NRIX
Nurix TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The bull case is that Nurix now has a clearer registrational path around bexobrutideg, with an ongoing pivotal Phase 2 study designed to support potential Accelerated Approval and a planned confirmatory Phase 3 start by mid-2026, while the balance sheet still showed $540.7 million at February 28, 2026 [#8-K-2026-04-08] [#10-Q-2026-04-08].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.5.
What can break
Execution risk around enrollment, data quality, and timing is significant for a company whose equity story is concentrated in bexobrutideg milestones and partner-program progress.
Momentum
96
Value
41
Sentiment
26
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $18.00 · Bull $26.00 · Bear $10.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $33.57
Why
Momentum96 · Δ7d -1.5
Value41 · Δ7d +0.1
Sentiment26 · Δ7d -1.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
96
26% active weight
Current posture
7d trendSoftening
Δ7d
-1.5
Δ21d
+12.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
26
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.8
Δ21d
+0.6
Why this grade
Composite grade C. Momentum 95.5 / Value 41.1 / Sentiment 25.7
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$2.44B
Beta
1.96
Shares Out
103.78M
P/E (TTM) · Derived
-7.7
P/S (TTM)
21.18
P/FCF (TTM) · Derived
-8.02
Rev YoY
-66.1%
EPS YoY
+17.4%
Gross Margin
+74.2%
Op Margin
-319.3%
Net Debt
-$537.21M
Current Ratio
6.01
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology